Trexquant Investment LP lifted its position in shares of Braskem S.A. (NYSE:BAK - Free Report) by 145.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 258,638 shares of the company's stock after purchasing an additional 153,401 shares during the quarter. Trexquant Investment LP owned 0.06% of Braskem worth $998,000 at the end of the most recent reporting period.
A number of other large investors have also made changes to their positions in BAK. HighTower Advisors LLC increased its holdings in shares of Braskem by 19.4% in the fourth quarter. HighTower Advisors LLC now owns 19,213 shares of the company's stock worth $74,000 after acquiring an additional 3,126 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Braskem by 876.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,427 shares of the company's stock worth $40,000 after acquiring an additional 4,871 shares during the last quarter. State Street Corp lifted its position in shares of Braskem by 2.3% in the third quarter. State Street Corp now owns 228,110 shares of the company's stock worth $1,674,000 after purchasing an additional 5,124 shares in the last quarter. R Squared Ltd acquired a new position in Braskem during the fourth quarter worth $44,000. Finally, Virtu Financial LLC bought a new position in Braskem in the third quarter valued at $88,000.
Wall Street Analyst Weigh In
Separately, Scotiabank cut shares of Braskem from a "sector outperform" rating to a "sector perform" rating in a research report on Monday, March 3rd.
Get Our Latest Stock Analysis on BAK
Braskem Stock Up 1.1 %
Shares of BAK traded up $0.04 during mid-day trading on Wednesday, hitting $3.34. 98,048 shares of the company's stock were exchanged, compared to its average volume of 813,812. The firm has a market cap of $1.33 billion, a price-to-earnings ratio of -0.94 and a beta of 1.80. The stock's 50-day simple moving average is $3.84 and its 200-day simple moving average is $4.71. Braskem S.A. has a 52 week low of $2.85 and a 52 week high of $9.21.
Braskem (NYSE:BAK - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.01). Braskem had a negative net margin of 9.88% and a negative return on equity of 439.59%. The company had revenue of $3.28 billion during the quarter, compared to analyst estimates of $3.52 billion. Analysts forecast that Braskem S.A. will post -0.77 earnings per share for the current fiscal year.
Braskem Company Profile
(
Free Report)
Braskem SA, together with its subsidiaries, produces and sells thermoplastic resins. The company operates through three segments: Brazil, United States and Europe, and Mexico. The Brazil segment produces and sells olefins, including ethylene, polymer and chemical grade propylene, butadiene, and butene-1; benzene, toluene, and xylenes products; fuels, such as automotive gasoline, liquefied petroleum gas, ethyl tertiary-butyl ether, and methyl tertiary-butyl ether; intermediates, such as cumene; aliphatics, aromatics, and hydrogenated solvents; and specialties comprising isoprene, dicyclopentadiene, piperylene, nonene, tetramer, polyisobutylene, and hydrocarbon resins.
See Also

Before you consider Braskem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Braskem wasn't on the list.
While Braskem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.